Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance.

Banzi, Rita
Cusi, Cristina
Randazzo, Concetta
Sterzi, Roberto
Tedesco, Dario
Moja, Lorenzo
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: Chinese herbal medicine (CHM) usage is expected to increase as women suffering from menopausal symptoms are seeking alternative therapy due to concerns from the adverse effects (AEs) associated with hormone therapy (HT). Scientific evidence for their effectiveness and safety is needed. OBJECTIVES: To evaluate the effectiveness and safety of CHM in the treatment of menopausal symptoms.

Zhu, Xiaoshu
Liew, Yuklan
Liu, Zhao Lan
Publication Title: 
Progress in Neuro-Psychopharmacology & Biological Psychiatry

The selective serotonin reuptake inhibitor (SSRI) ProzacÆ (fluoxetine) is widely prescribed for the treatment of depression and anxiety-related disorders. While extensive research has established that fluoxetine is safe for adults, safety is not guaranteed for (unborn) children and adolescents. Some clinical studies have reported adverse outcomes, such as premature birth, neonatal cardiovascular abnormalities, and pulmonary hypertension in children whose mothers used SSRIs during pregnancy.

Olivier, J. D. A.
Blom, T.
Arentsen, T.
Homberg, J. R.
Publication Title: 
Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology

Chronic social defeat stress in mice produces a susceptible phenotype characterized by several behavioral abnormalities consistent with human depression that are reversed by chronic but not acute exposure to antidepressant medications. Recent work in addiction models demonstrates that the transcription factor ?FosB and protein kinase calmodulin-dependent protein kinase II (CaMKII) are co-regulated in nucleus accumbens (NAc), a brain reward region implicated in both addiction and depression models including social defeat.

Robison, A. J.
Vialou, Vincent
Sun, Hao-Sheng
LabontÈ, Benoit
Golden, Sam A.
Dias, Caroline
Turecki, Gustavo
Tamminga, Carol
Russo, Scott
Mazei-Robison, Michelle
Nestler, Eric J.
Publication Title: 
The American Journal of Psychiatry

OBJECTIVE: The authors compared the effectiveness of fluoxetine and desipramine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Americans and examined the role of whole-exome functional gene variations in the patients' antidepressant response. METHOD: A total of 232 Mexican Americans who met DSM-IV criteria for major depressive disorder were randomly assigned to receive 8 weeks of double-blind treatment with desipramine (50-200 mg/day) or fluoxetine (10-40 mg/day) after a 1-week placebo lead-in period.

Wong, Ma-Li
Dong, Chuanhui
Flores, Deborah L.
Ehrhart-Bornstein, Monika
Bornstein, Stefan
Arcos-Burgos, Mauricio
Licinio, Julio
Publication Title: 
The Journal of Clinical Psychiatry

BACKGROUND: In general, effective treatments for trichotillomania have been elusive. Although behavioral therapies and hypnosis have provided benefits to some, adult patients with chronic hair pulling have often proved refractory to treatment. Medication has generally been unhelpful until the recent introduction of serotonin reuptake inhibitors for the treatment of this condition. Furthermore, there has been little systematic study of the clinical characteristics of these patients.

Winchel, R. M.
Jones, J. S.
Stanley, B.
Molcho, A.
Stanley, M.
Publication Title: 
Physiology & Behavior

Nitrazepam (0.5-10 mg/kg, IP) dose dependently induced behavioral sleep in day-old chicks. Fluoxetine (0.1-1 mg/kg) did not produce sleep in the young birds, but the 5-HT reuptake inhibitor (0.1 and 0.5 mg/kg) potentiated nitrazepam (0.5 and 1.0 mg/kg)-induced hypnosis. Doses (0.5 and 1 mg/kg) of the benzodiazepine that did not produce sleep in any or all the chicks, when administered alone, induced sleep in some or all the chicks in the presence of fluoxetine (0.1 and 0.5 mg/kg).

Hussaini, I. M.
Musa, M. H.
Publication Title: 
Journal of Autoimmunity

Systemic lupus erythematosus (SLE) is an autoimmune disease associated with more than 100 different autoantibodies, some of which may be associated with specific neuropsychiatric (NPSLE) manifestations. Injection of anti-P ribosomal antibodies (anti-P) directly to the brain ventricles of mice induces depression manifested by increased immobility time in the forced swim test (FST). METHODS: Mice were injected intracerebroventricularily (ICV) with affinity-purified human anti-P antibodies or normal commercial IgG as control.

Katzav, Aviva
Ben-Ziv, Tal
Chapman, Joab
Blank, Miri
Reichlin, Morris
Shoenfeld, Yehuda
Publication Title: 

RATIONALE: Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder. Little is known about fluoxetine's influence on mood changes after quitting smoking, which often resemble sub-clinical depression. OBJECTIVES: The present study, a re-analysis of previously published data (Niaura et al. 2002), examined fluoxetine's effect on changes in negative and positive affect following quitting smoking.

Cook, Jessica Werth
Spring, Bonnie
McChargue, Dennis E.
Borrelli, Belinda
Hitsman, Brian
Niaura, Raymond
Keuthen, Nancy J.
Kristeller, Jean
Publication Title: 
Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology

OBJECTIVE: To assess whether pretreatment theta current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC) differentiates responders from non-responders to antidepressant medication or placebo in a double-blinded study. METHODS: Pretreatment EEGs were collected from 72 subjects with Major Depressive Disorder (MDD) who participated in one of three placebo-controlled trials. Subjects were randomized to receive treatment with fluoxetine, venlafaxine, or placebo.

Korb, Alexander S.
Hunter, Aimee M.
Cook, Ian A.
Leuchter, Andrew F.


Subscribe to RSS - Fluoxetine